In this randomized controlled trial, lixisenatide reduced motor disability progression in Parkinson’s patients.
2. Individuals in the lixisenatide group experienced greater gastrointestinal side effects rates than individuals in the placebo group.
Evidence Rating Level: 1 (Excellent)
Parkinson’s breakthrough: Researchers find way to halt disease progressionAustralian trial gives new hope for Parkinson’s disease treatment
Diabetic drug could slow the progression of Parkinson’s diseaseCough syrup drug being trialed as Parkinson’s treatmentParkinson’s UK Award Targets New Therapies that slows disease progression
